eMedevents
  • 141522+ Medical Conferences
  • 273 Specialties
  • 10674 Organizers
  • 153433 Speakers
  • 156 Countries
  • 4613 Cities
47174+
CME Conference Registrations Sold
Home  >  Conferences  >  17th Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC)
CME : 27.00

17th Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC)

Dec 04 - 07, 2019   |   Los Angeles, California  United States of America
Specialties : Nephrology   |   Nutrition   |   Endocrinology, Metabolism and Diabetes   |   Cardiology   |   Endocrinology
  Register Now
Conference Brochure

17th Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC) is organized by The Metabolic Institute of America (TMIOA) and will be held from Dec 04 - 07, 2019 at Hilton Los Angeles/Universal City, Los Angeles, California, United States of America. This CME Conference has been approved for a maximum of 27.00 AMA PRA Category 1 Credits.

Target Audience:
This educational initiative is designed for cardiologists, endocrinologists, gastroenterologists, oncologists, internists, diabetologists, OBGYNs, pediatricians, dietitians, nurse practitioners, pharmacists, and any other health care professionals who are interested in insulin resistance, diabetes, obesity, cardiovascular disease, and multiple metabolic mechanisms’ effects on health and society, as well as on potential treatment and prevention.

Program Description:
This Conference is a unique and exciting multidisciplinary program. The Congress is the premiere global meeting dedicated to diabetes, obesity, lipids, cardiovascular disease (CVD), and energy balance, linking basic research to clinical practice, and highlighting our theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

For more than a decade, the WCIRDC has brought researchers, physicians and healthcare professionals together for a distinctive international program that bridges the latest developments from the bench to bedside. “I heard it first at the Congress” is a frequent remark from the audience over the years, many of whom attend year after year. Researchers present their latest data on everything from biomarkers to new physiologic insights to new ideas for therapies. WCIRDC offers attendees a unique experience to interact with the distinguished global faculty for a collaborative experience that explores the newest understanding of metabolic diseases and the development of future therapeutic modalities.

Since Dr. Gerald Reaven’s pioneering work crystallized the relationship between insulin resistance (IR), diabetes, and CVD, the Congress’ focus has expanded to the fat cell, lipids, the kidney, the brain, bone, energy metabolism, inflammation, CVD complications and cancer.  The Congress addresses atherosclerosis, hypertension, and hypercoagulation as well as pharmaceutical interventions like incretins, SGLT2i’s and PCSK9i’s to name a few. The goal is to understand the state of the art pathophysiology and to develop appropriate comprehensive clinical management strategies.

For primary care clinicians, the Congress will feature a series of workshops and “meet the expert” panels addressing the clinical management of kidney disease, diabetes, obesity, lipids, the high risk CVD patients and more. To make basic and clinical research topics relevant to clinical medicine, there will be commentaries on its clinical implications by recognized clinical experts. The Congress’ intimate setting promotes a lot of personal contact between participants and the faculty wherein everyone learns from the free flow of questions and personal observations.

The Congress attracts state-of-the-art abstracts from around the globe. These abstracts will be published in Endocrine Practice (ISSN: 1530-891X), a peer-reviewed journal published twelve times a year, is the official journal of the American Association of Clinical Endocrinologists (AACE).

Typically, articles about the meeting are published in several medical journals, such as Endocrine Practice, Metabolism, The Journal of Diabetes, and Diabetes Care.

Program Objectives:
The program is designed to evaluate both the clinical and basic science aspects of diabetes, obesity, dyslipidemia and CVD, by focusing on insulin resistance, hyperinsulinemia, fat cells, the heart, the kidneys, and energy metabolism.  The goal is to understand its pathophysiology, and to develop appropriate comprehensive clinical management plans.

Upon completion of this meeting, participants should be able to:
• Provide comprehensive management of diabetes, by addressing obesity, hypertension, dyslipidemia, and cardiovascular risks.
• Discuss the role of obesity in the development of cardiometabolic conditions
• Discuss the role of incretins in the management of obesity, diabetes, and prevention of CVD
• Be aware of the results of cardiovascular outcome trials and understand the potential role of SGLT2i & GLP1ra in managing Diabetes and CVD
• Evaluate the extent of macrovascular and microvascular disease in diabetes and obesity
• Address the risks of heart disease in patients with diabetes
• Explain the role of lipids, in particular low-density lipoprotien (LDL-C) and non- HDL-C, in the development of atherosclerosis
• Examine the role of PCSK9 and the newly developed monoclonal antibodies- the PCSK9 inhibitors in LDL homeostasis and on the contemporary approaches to management and prevention of CVD
• Describe contemporary approaches to congestive heart failure
• Explain the relationship of the kidney to insulin resistance, diabetes and  CVD
• Explain the pathophysiology and complications of fatty liver disease and its relationship to diabetes and CVD
• Discuss the role of SGLT2i in the management of diabetes its potential role beyond glycemia and known complications.
• Evaluate bariatric surgery and newly-developed procedures, as well as devices and their effect on weight loss and hormones, and their long-term outcomes

View All Attending

Jennifer Johnson
Jennifer Johnson

Endocrinology

Eunchul Jang
Eunchul Jang

Occupational Medicine

Eva Skulteti
Eva Skulteti

Pharmaceuticals

Tracking

Xuemei Yao
Xuemei Yao

Cardiology

Conference Details

Scientific Poster : View Poster
Session Brochure : Download Session Brochure
Social Media Info :    

Registration Desk

Contact No. : 1-818-342-1889

Email:
jeannine@tmioa.com
info@tmioa.com
Abstraction date:
November 11, 2019

Registration

Registration Type Last Date Price
General Attendee - Late fee 30 Nov,2019 USD 650.00
Fellow/Resident - Late fee 30 Nov,2019 USD 400.00
Students - Late fee 30 Nov,2019 USD 175.00
Single day Tickets - Staurday fee 30 Nov,2019 USD 250.00
View Expired Tickets
view all
  • Drive Walk Transit Bicycle

Venue Address

Hilton Los Angeles/Universal City
555 Universal Hollywood Dr, Universal City
Los Angeles, California, United States of America

Official Hotel

Hilton Los Angeles/Universal City,

555 Universal Hollywood Dr, Universal City,

Los Angeles, California, United States of America 91608,

+1 818-506-2500

Plan Your Travel

 
 
 
 

Please Rate this Conference

 0.0
 0.0
 0.0
 0.0
 0.0

Reviews Given by People

No Reviews available. Be the first to write a review.

Hotels Near Venue

Plaza la Reina
7.19 miles from venue
Price : USD 569.00 Per Night
Kimpton Hotel Palomar Los Angeles Beverly Hills
6.99 miles from venue
Price : USD 199.20 Per Night
W Los Angeles – West Beverly Hills
6.98 miles from venue
Price : USD 269.00 Per Night
Mr C Beverly Hills
6.12 miles from venue
Price : USD 399.00 Per Night
Close

Session Details

Session Topic Start Time End Time Location Description Speakers
Close

Workshop Details

Title Start Time End Time Workshop Fee

Subscribe to our Newsletter

x

Subscribe to our newsletter and receive updates on medical conferences, board review courses and news